Venetoclax + Zanubrutinib for Chronic Lymphocytic Leukemia

This trial explores the effectiveness of combining the drugs venetoclax and zanubrutinib to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Venetoclax may block a protein that helps cancer cells survive, while zanubrutinib might inhibit cancer cell growth. The trial aims to determine if these drugs together can safely reduce cancer cells in individuals with CLL or SLL who have not received treatment before or have not been treated in over two years. This trial may suit those diagnosed with CLL or SLL who haven't had recent treatment or completed initial treatment at least two years ago. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

Research shows that the combination of venetoclax and zanubrutinib is generally well-tolerated by patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). One study found that the most common serious side effects included low white blood cell counts (24%), high blood pressure (9%), and diarrhea (6%). While monitoring these side effects is necessary, the treatment is considered safe overall.

Researchers are excited about Venetoclax and Zanubrutinib for Chronic Lymphocytic Leukemia (CLL) because these drugs offer a novel approach compared to standard treatments like chemoimmunotherapy or other BTK inhibitors. Venetoclax works by targeting and inhibiting a protein called BCL-2, which helps cancer cells survive, leading to their death. Zanubrutinib, a newer BTK inhibitor, may offer better selectivity and fewer side effects than older drugs like Ibrutinib. Together, these drugs aim to improve patient outcomes by effectively targeting cancer cells with potentially fewer side effects.

Studies have shown that combining venetoclax and zanubrutinib effectively treats chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In this trial, participants in both Cohort I and Cohort II will receive this combination. Research indicates that this treatment achieves an 87% progression-free survival (PFS) rate at 36 months, meaning most patients did not experience cancer progression over three years. Additionally, earlier studies found that 95% of patients responded well to the treatment. This combination blocks proteins that help cancer cells grow, potentially stopping the cancer from spreading. These findings suggest that this combination has strong potential to effectively manage CLL and SLL.⁶⁷⁸⁹¹⁰